First Week of December 18th Options Trading For Kodiak Sciences (KOD)

Stock Options Channel highlights income-oriented option strategies on Kodiak Sciences (KOD): a $27 put trading with a $9.00 bid would set an effective share cost basis of $18.00 if assigned, is ~2% out‑of‑the‑money, carries a 72% probability of expiring worthless and implies a 33.33% return on cash (36.21% annualized). On the call side, a $32 covered call with a $9.00 bid against a $27.60 stock price is ~16% out‑of‑the‑money, would yield 48.55% if called at the Dec. 18 expiration, has a 32% chance to expire worthless (32.61% boost, 35.42% annualized); implied vols are ~120% (put) and 126% (call) versus a 12‑month trailing volatility of 116%.

Analysis

Market structure: The present risk/reward favors option sellers and patient buyers willing to be long via assignment — cash‑secured $27 puts yield 33% over ~30–60 days (annualized ~36%) while covered calls can deliver ~48.5% to $32. High implied vol (120–126%) vs realized (116%) signals elevated demand for tail protection/speculation in KOD and implies dealers are being paid to warehouse gamma; this concentrates downside risk into sellers if a binary event hits.

Risk assessment: Tail risks are classic biotech binaries — clinical/FDA failure or a dilutive secondary can easily cut equity by 40–70% (low probability, high impact). Immediate (days): theta decay benefits sellers; short term (weeks/months): assignment/dilution risk around any filings or readouts; long term: fundamental pipeline success drives >100% moves. Hidden dependency: strategies assume IV mean reversion; an IV spike (≥30%) will blow up naked sellers and materially change probabilities.

Trade implications: Tactical: prefer structured, limited‑downside option sells (cash‑secured puts or verticals) sized 0.5–2% portfolio rather than naked exposure. Pair idea: long KOD via put‑sale (idiosyncratic) hedged by short equal notional XBI to remove sector beta. If owning stock, use covered calls to monetize a neutral-to-bullish view but cap upside to $32 through Dec18.

Contrarian angles: Consensus underweights dilution risk and overweights greeks‑based probability charts — those assume static capital structure. The premium is high but not irrational; selling naked puts is likely underpriced if a secondary emerges. Historical parallels: biotech pre-readout IV often collapses post‑binary; plan exits tied to readout/dilution signals to avoid being on wrong side of gamma.

Key Decisions for Investors

• Establish a measured cash‑secured put position in KOD: sell Dec 18 $27 puts sized to 0.5–1.5% of portfolio (each contract = $2,700 cash reserve, collect ~$900). Use this to convert desired buy exposure at an effective basis ≈ $18, and close if KOD < $20 or if IV rises >30% from current.
• Prefer a defined‑risk put spread if you want exposure but cap tail risk: sell $27 / buy $24 Dec 18 put spread sized to 0.5–1% of portfolio. This limits maximum downside to ~$300 per contract minus net credit and preserves the ~30%+ premium capture.
• If long the equity, implement covered calls: buy up to 1–2% position in KOD and sell Dec 18 $32 calls to lock a ~48.5% upside to expiry; buy back calls if KOD trades >$34 pre‑expiry or if IV collapses >25% (lock profits).
• Risk control & monitoring: reduce KOD option/stock exposure by 50% if SEC filings show >5% share count increase or if company announces a clinical readout/FDA action within 30 days; avoid naked short vol exposure in biotech—use verticals or hedged pairs instead.